Copyright: ©Author(s) 2026.
World J Hepatol. Jun 27, 2026; 18(6): 117996
Published online Jun 27, 2026. doi: 10.4254/wjh.117996
Published online Jun 27, 2026. doi: 10.4254/wjh.117996
Table 3 Modified Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B scoring
| Modified Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B scoring | ||
| Sex | Female | 0 |
| Male | 2 | |
| Age (years) | 30-34 | 0 |
| 35-39 | 1 | |
| 40-44 | 2 | |
| 45-49 | 3 | |
| 50-54 | 4 | |
| 55-59 | 5 | |
| 60-65 | 6 | |
| ALT (U/L) | < 15 | 0 |
| 15-44 | 1 | |
| ≥ 45 | 2 | |
| HBeAg status | Negative | 0 |
| Positive | 2 | |
| LSM (kPa) | < 8.0 | 0 |
| 8.0-13.0 | 2 | |
| > 13.0 | 4 | |
- Citation: Mian I, Subhaharan D, Haig A, Cox R, Masood T, Braund A, Funakoshi N. Comparing validated hepatocellular carcinoma risk scores for chronic hepatitis B against current Australian surveillance guidelines. World J Hepatol 2026; 18(6): 117996
- URL: https://www.wjgnet.com/1948-5182/full/v18/i6/117996.htm
- DOI: https://dx.doi.org/10.4254/wjh.117996